Epidemiology of malignant melanoma

Surgical Clinics of North America

Volumn 83, Issue 1, 2003, Pages 1-29

  Desmond, Renee A ^a,b   Soong, Seng jaw ^a  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SUSCEPTIBILITY; DIET; GENETIC SUSCEPTIBILITY; HUMAN; MELANOMA; ORAL CONTRACEPTION; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SKIN PROTECTION; SMOKING; ULTRAVIOLET IRRADIATION; UNITED STATES;

FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; RISK FACTORS; SKIN NEOPLASMS; UNITED STATES;

EID: 0037304077     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00092-0     Document Type: Review

References (74)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC cancer base no.5. Lyon: IARC Press; 2001.
2. Jones WO, Harman CR, Ng AKT, et al. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg 1999;23:732-5.
3. Serraino D, Fratino L, Gianni W, et al. Epidemiological aspects of cutaneous malignant melanoma (Review). Oncol Rep 1998;5:905-9.
4. Gallagher RP, Alwood JM, editors. Epidemiological aspects of cutaneous malignant melanoma. Boston: Kluwer Academic Publishers; 1994.
5. Dennis LK, White E, Lee JAH. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control 1993;4:93-100.
6. Bulliard J-L, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999;10:407-16.
7. van der Rhee JH, van der Spek-Keijser LMT, van Westering R, et al. Increase in and stabilization of incidence and mortality of primary cutaneous malignant melanoma in western Netherlands 1980-5. Br J Derm 1999;140:463-7.
8. SEER cancer incidence public use database. 1973-1998, Bethesda (MD): US Dept. HHS Public Health Service, NCI; 2001.
9. Lee JAH. The systemic relationship between melanomas diagnosed in situ and when invasive. Melanoma Res 2001;11:523-9.
10. Dennis LK. Analysis of the melanoma epidemic, both apparent and real. Arch Dermatol 1999;135:275-80.
11. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999;40:35-42.
12. Horn-Ross P, Holly EA, Brown SR, et al. Temporal trends in the incidence of cutaneous malignant melanoma among Caucasians in the San Francisco Oakland MSA. Cancer Causes Control 1991;2:299-305.
13. MacLennan R, Green AC, McLeod GRC, et al. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992;84:1427-32.
14. Lipsker DM, Hedelin G, Heid E. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999;135:1451-6.
15. Garbe C, McLeod GRC, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000;89:1269-78.
16. Vinceti M, Bergomi M, Borciani N, et al. Rising melanoma incidence in an Italian community from 1986 to 1997. Melanoma Res 1999;9:97-103.
17. Brochez L, Naeyaert J-M. Understanding the trends in melanoma incidence and mortality: where do we stand? Eur J Dermatol 2000;10:71-6.
18. Thörn M, Pontén F, Johansson A-M, et al. Rapid increase in diagnosis of cutaneous melanoma in situ in Sweden, 1968-1992. Cancer Detect Prev 1998;22:430-7.
19. Bulliard J-L, Cox B, Elwood JM. Comparison of the site distribution of melanoma in New Zealand and Canada. Int J Cancer 1997;72:231-5.
20. Elwood JM, Gallagher RP. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J Cancer 1998;78:276-80.
21. Dennis LK. Melanoma incidence by body site: effects of birth-cohort adjustment. Arch Dermatol 1999;135:1533-4.
22. Pedlow PJ, Walsh MY, Patterson CC, et al. Cutaneous malignant melanoma in Northern Ireland. Br J Cancer 1997;76:124-6.
23. Gillgren P, Månsson-Brahme E, Frisell J, Ossordo M, et al. Epidemioloigcal characteristics of cutaneous malignant melanoma of the head and neck. Acta Oncologica 1999;38:1069-74.
24. Boisseau-Garsaud A-M, Garsaud P, Ossondo M, et al. Trends in melanoma in whites living in the French West Indies (Martinique). Dermatology 1998;196:365-6.
25. Garsaud P, Boisseau-Garsaud A-M, Ossondo M, et al. Epidemiology of cutaneous melanoma in the French West Indies (Martinique). Am J Epidemiol 1998;147:66-8.
26. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma. Cancer 1998;83:1664-78.
27. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998;34(Suppl 3):S3-6.
28. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
29. Weinstock MA. Do sunscreens increase or decrease melanoma risk: an epidemiologic investigation. J Invest Dermatol 1999;4:97-100.
30. Rousch GC, McKay L, Holford TR. A reversal in the long-term increase in deaths attributable to malignant melanoma. Cancer 1992;69:1714-20.
31. Devesa SS, Grauman DJ, Blot, WJ, et al. Atlas of cancer mortality in the United States 1950-1994. NIH Pub No. 99-4564. Bethesda (MD); 1999.
32. Lee JAH. Latitude, coastal or interior location and the evolution of the melanoma epidemic in the United States. Melanoma Res 1997;7:179-88.
33. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997;277:1439-44.
34. Ródenas JM, Delgado-Rodríguez M, Farinas-Alvaraez C, et al. Melanocytic nevi and risk of cutaneous malignant melanoma in Southern Spain. Am J Epidemiol 1997;145:1020-9.
35. Breitbart M, Garbe C. Büttner, et al. Ultraviolet light exposure, pigmentary traits and the development of melanocytic nevi and cuataneous melanoma. Acta Derm Venereol 1997;77:374-8.
36. Bataille V, Grulich A, Sasieni P, et al. The association between nevi and melanoma in populations with different livels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998;77:505-10.
37. Lock-Andersen J, Drzewiecki KT, Wulf HC. Eye and hair colour, skin type and constitutive skin pigmentation as risk factors for basal cell carcinoma and cutaneous malignant melanoma. Acta Derm Venereol 1999;79:74-80.
38. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation: N Engl J Med 1999;340:1341-48.
39. Sahin S, Levein L, Kopf AW, et al. Risk of melanoma in medium-sized congenital melanocytic nevi a follow-up study. J Am Acad Dermatol 1998;39:428-33.
40. Bhatia S, Estrada-Bastres L, Maryon T, et al. Second primary tumors in patients with cutaneous malignant melanoma. Cancer 1999;86:2014-20.
41. Levi F, LaVecchia C, Randimbison L, et al. Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer 1997;72:776-9.
42. Retsas S, Mohith A, Bell J. Melanoma and additional primary cancer. Melanoma Res 2000;10:145-52.
43. Kopf AW, Hellman LJ, Rogers GS, et al. Familial malignant melanoma. JAMA 1986;256:1915-9.
44. Kamb A, Shattuck-Eidends D, Eleles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
45. Ang CG, Kelly JW, Fritschi L, et al. Characteristics of familial and non-familial melanoma in Australia. Melanoma Res 1998;8:459-64.
46. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature (Lond) 1994;372:773-6.
47. Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998;77:843-8,
48. Landi MR, Baccarelli A, Tarone RE, et al. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002;94:94-101.
49. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198-203.
50. Autier P, Doré JF, Gefeller O, et al. Melanoma risk and residence in sunny areas. Br J Cancer 1997;76:1521-4.
51. Tsao H, Sober AJ. Ultraviolet radiation and malignant melanoma. Clin Dermatol 1998;16:67-73.
52. Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks, Cancer Epidemiol Biomarkers Prev 2000;9:291-7.
53. Karagas MR, Stannard VA, Mott CA, et al. Use of tanning devices and risk of basal cell and squameous cell skin cancers: J Natl Cancer Inst 2002;94:224-6.
54. Westerdahl J, Ingvar C, Måsbäck A, et al. Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br J Cancer 2000;82:1593-9.
55. La Vecchia C. Sunscreens and the risk of cutaneous mealignant melanoma. Eur J Cancer Prev 1999;8:267-9.
56. Weinstock MA. Issues in the epidemiology of melanoma. Hematol Oncol Clin North Am 1998;4:681-98.
57. Autier P, Doré J-F, Renard F, et al. Melanoma and sunscreen use: need for studies representative of actual behaviors. Melanoma Research 1997;7(Suppl 2):S115-20.
58. Austin DF, Reynolds PJ, Snyder MA, et al. Malignant melanoma among employees of Lawrence Livermore National Laboratory. Lancet 1981;2(8249):712-6.
59. Austin DF, Reynolds P. Investigation of an excess of melanoma among employees of the Lawrence Livermore National laboratory. Am J Epidemiol 1997;145:524-31.
60. Moore DH, Patternson HW, Hatch R, et al. Case-control study of malignant melanoma among employees of Lawrence Livermore national laboratory. Am J Ind Med 1997;32:377-91.
61. Ward EM, Burnett CA, Ruder A, et al. Industries and cancer. Cancer Causes Control 1997;8:356-70.
62. Langard S, Rosenberg J, Anderson A, et al. Incidence of cancer among workers exposed to vinyl chloride in polyvinyl chloride manufacture. Occup Environ Med 2000;57:65-8.
63. Rafnsson V, Hrafnkelsson J, Tulinius H. Incidence of cancer among commercial airline pilots. Occup Enviorn Med 2000;57:175-9.
64. Ron E, Preston DL, Kishikawa M, et al. Skin tumor risk among atomic-bomb survivors in Japan. Cancer Causes Control 1998;9:393-401.
65. Vinceti M, Rovesti S, Bergomi M, et al. The epidemiology of selenium and human cancer. Tumori 2000;86:105-18.
66. Vinceti M, Rothman KJ, Bergomi M, et al. Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 1998;7:853-6.
67. Breslow RA, Alberg AJ, Helzlsouer KJ, et al. Serological precursors of cancer: malignant melanoma, basal and squameous cell skin cancer, and prediagnostic levels of retinal, betacarotene, lycopene, alpha-tocopherol, and selenium. Cancer Epidemol Biomarkers Prev 1995;4:837-42.
68. Knekt P, Aromaa A, Maatela J, et al. Serum micronutrients and risk of cancers of low incidence in Finland. Am J Epidemiol 1991;134:356-61.
69. Le Marchand L. Dietary factors in the etiology of melanoma. Clin Dermatol 1992;10:79-82.
70. Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer 1997;71:600-4.
71. Merimsky O, Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998;16:585-8.
72. Osterlind A. Malignant melanoma in Denmark: occurrence and risk factors. Acta Oncol 1990;29:833-54.
73. Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997;25:309-15.
74. Keyfitz N. Sampling variance of standardized mortality rates. Hum Biol 1966;38:309-17.